Acetylcysteine

3月16日，百花医药涨1.63%，成交额1.75亿元，换手率4.85%，总市值36.03亿元。异动分析青蒿素+细胞免疫治疗+流感+新疆振兴+创新药1、*ST百花6月20日在互动平台表示，旗下公司西姆欧已入选昆药集团青蒿素临床研究合作伙伴，相关合作尚需推进，上市公司会关注该合作推进情况。2、2022年9月5日互动易回复：公司旗下礼华生物围绕“1个中心+4大平台”服务模式，建立了市级企业技术研究中心，市级生物等效性工程技术一体化平台、生理药动学PBPK的建模与模拟平台、体内体外相关性大数据预测平台、先进性疗法前沿医学平台，开展早期临床研究、Ⅰ-Ⅳ期临床试验、生物等效性临床试验、定量药理特色服务、细胞治疗与基因治疗。3、2022年12月13日公司互动回复：目前公司治疗流感的化药主要研发项目有：止咳祛痰退烧相关药品，如盐酸溴己新口服溶液、注射液、吸入溶液，羧甲司坦口服液，乙酰半胱氨酸口服溶液、吸入溶液、注射液对乙酰氨基酚等。4、07年农六师国资以持有70%的天然物产股权认购公司定向发行的股份，公司主业改为焦煤开采和销售。(天然物产以4700万元和1.13亿元受让新疆拜城县梅斯布拉克煤矿一井田和二井田的采矿权，地质储量约8500万吨，以1700万元受让三井田的探矿权。梅斯布拉克煤矿60万吨/年建设项目已被列入国家开发银行开发性金融贷款计划。) 公司现拥有煤炭资源储量共计2.9亿吨，主要煤种为主焦煤和气煤，均为我国煤炭稀缺煤种，与普通动力煤相比经济价值较高。公司作为新疆生产建设兵团第一家上市公司和农六师所属唯一一家上市公司，倍受关注。 公司表示将积极争取股东方的大力支持，充分利用兵团及资本市场资源优势，以资源类投资控股型公司为发展方向，着力打造兵团支柱企业。5、新疆百花村医药集团股份有限公司的主营业务是新药早期发现与筛选、药物CMC开发、临床试验、注册申报、BE/PK生物样品分析及药学检测服务、临床SMO及数据服务、MAH服务、API及中间体技术服务。2025年9月26日互动易， 临床研究服务领域，协助多项创新药进入早期临床、推进多项改良型新药进入关键临床阶段，同步构建溶瘤病毒、乙肝疫苗、肿瘤疫苗等前沿医学技术转化体系，未来将重点布局精准给药、新型治疗技术方向，并持续强化“药学-临床-注册”全链条协同优势。(免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断)资金分析今日主力净流入201.75万，占比0.01%，行业排名14/52，该股当前无连续增减仓现象，主力趋势不明显；所属行业主力净流入-4.18亿，连续3日被主力资金减仓。区间今日近3日近5日近10日近20日主力净流入201.75万764.29万2066.69万-571.29万-3290.51万主力持仓主力轻度控盘，筹码分布较为分散，主力成交额4373.66万，占总成交额的10.88%。技术面：筹码平均交易成本为9.54元该股筹码平均交易成本为9.54元，近期该股获筹码青睐，且集中度渐增；目前股价靠近压力位9.44，谨防压力位处回调，若突破压力位则可能会开启一波上涨行情。公司简介资料显示，新疆百花村医药集团股份有限公司位于新疆乌鲁木齐市天山区中山路南巷1号，成立日期1996年6月21日，上市日期1996年6月26日，公司主营业务涉及新药早期发现与筛选、药物CMC开发、临床试验、注册申报、BE/PK、生物样品分析及药学检测服务、临床SMO及数据服务、MAH服务、API及中间体生产供应,可为客户提供从药物发现、药学CMC开发、临床试验与申报注册的全过程一站式外包和技术成果转化服务。主营业务收入构成为：临床试验49.39%，医药研发及一致性评价42.67%，租赁及物业服务业务6.69%，其他收入0.94%，其他(补充)0.31%。百花医药所属申万行业为：医药生物-医疗服务-医疗研发外包。所属概念板块包括：生物医药、流感、创新药、减肥药、肝炎概念等。截至9月30日，百花医药股东户数3.32万，较上期增加10.56%；人均流通股11584股，较上期减少9.49%。2025年1月-9月，百花医药实现营业收入2.99亿元，同比增长2.74%；归母净利润3267.42万元，同比增长36.41%。分红方面，百花医药A股上市后累计派现612.75万元。近三年，累计派现0.00元。声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系biz@staff.sina.com.cn。

NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a median T100 of 1.69 minutes versus 3.42 minutes (p=0.033). At 5 minutes, 88.4% of subjects receiving NS002 reached the threshold compared to 64.6% with EpiPen® NS002 continued to demonstrate a favorable safety pro no serious adverse events reported and comparable pharmacodynamic response to EpiPen® across all participants Pivotal study initiation planned for fourth quarter of 2026 Conference call and webcast scheduled for 8:00 a.m. EDT today TEL AVIV, Israel, March 16, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced positive top line results from its Phase 2 clinical study of NS002, the Company's investigational intranasal epinephrine powder formulation for the treatment of anaphylaxis. The comprehensive analysis demonstrated that NS002 achieved significantly faster and higher early epinephrine absorption compared to intramuscular EpiPen® autoinjector. The Company plans to initiate its pivotal clinical study in fourth quarter of 2026. The open-label Phase 2 study enrolled 50 healthy adults with a history of allergic rhinitis. All subjects received a single and repeat dose of NS002 and intramuscular EpiPen ® with and without a nasal allergic challenge (“NAC”). This robust study design provided comprehensive data supporting NS002's clinical utility across multiple administration scenarios that patients may encounter during actual anaphylactic emergencies. "We've successfully demonstrated NS002's differentiated and potentially superior product pro to traditional epinephrine autoinjectors," said Dan Teleman, Chief Executive Officer of Nasus Pharma. "NS002 was specifically engineered for superior epinephrine delivery, powered by our proprietary Nasax® powder platform, and designed as a needle-free, easy to use and carry device. The compelling top line data significantly strengthens our conviction that NS002 has the potential to become a leading product in anaphylaxis treatment. These positive results represent a major milestone for Nasus Pharma as we advance NS002 towards the pivotal study and future marketing applications. We remain on track to initiate our pivotal study in the fourth quarter of 2026, bringing us closer to delivering this potentially life-saving innovation to patients worldwide." Top Line Analysis Key Results: The top line Phase 2 analysis demonstrated multiple significant advantages for NS002 across key pharmacokinetic and pharmacodynamic parameters: Speed to Therapeutic Threshold : After a single administration, NS002 achieved the critical 100 pg/mL plasma epinephrine threshold with a median T100 of 1.69 minutes versus 3.42 minutes for EpiPen® (p=0.033). At 2.5 minutes, 67.4% of participants receiving NS002 reached the therapeutic threshold compared to 27.1% with EpiPen® (p=0.0001). At 5 minutes, 88.4% of NS002 subjects reached the threshold compared to 64.6% with EpiPen® (p=0.0081). By 10 minutes, approximately 95% of participants receiving NS002 reached the therapeutic threshold. Time to Peak Concentration : NS002 reached peak concentration (“Tmax”) in a median of 15 minutes compared to 19.8 minutes with EpiPen®, demonstrating consistently faster epinephrine delivery. Critical Window Drug Exposure : Total epinephrine absorption in the critical 10-minute therapeutic window following administration was approximately 50% higher with NS002, with AUC statistically significantly higher in the first 5–10 minutes compared to EpiPen®. Repeat Dose Performance: Repeat administration of NS002 with or without a NAC maintained consistent pharmacokinetic advantages over EpiPen®, a clinically significant finding given that patients experiencing severe anaphylaxis may require a repeat dose to fully resolve symptoms. Peak Plasma Concentrations: Across multiple scenarios, NS002 demonstrated comparable peak plasma concentration (“Cmax”) compared to EpiPen®, with repeat dosing showing particularly strong performance. Safety and Tolerability Profile: NS002 demonstrated a favorable safety and tolerability pro with previous studies, with no serious adverse events reported. These results demonstrated that NS002 has the potential to exceed EpiPen® performance across the full spectrum of real-world conditions, including the challenging NAC environment that simulates scenarios patients may encounter during actual allergic reactions. The analysis showed statistically significant improvements in time to therapeutic threshold (T100) and in the proportion of subjects reaching the therapeutic epinephrine threshold within the first minutes following administration. Conference call and webcast Nasus Pharma will host a conference call and webcast today at 8:00 a.m. EDT to review and discuss the final analysis data from the Phase 2 repeated dose clinical study. Individuals may dial in to the conference call by dialing 1-877-704-4453 from the U.S. or by dialing +1-201-389-0920 from outside the U.S., or view the webcast HERE . A replay of the webcast will be hosted on Nasus Pharma’s investor relations website at . About Nasus Pharma Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus Pharma’s intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle-free, easy-to-use alternatives. Nasus Pharma’s proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. For further information about the Company, please visit or follow on Twitter (X) or LinkedIn . Forward Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. Words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will”, “would,” or the negative of these words, similar expressions or variations of such words are intended to identify forward-looking statements. For example, Nasus Pharma is using forward looking statements in this press release when it discusses: the belief that the full analysis from the Phase 2 clinical study demonstrates NS002’s superior epinephrine delivery compared to traditional epinephrine autoinjectors; the belief that NS002 has the potential to become a leading product in anaphylaxis treatment; the expectation that the top line data from the Phase 2 study will support advancement of NS002 toward a pivotal study and future marketing applications; the potential of NS002 to exceed EpiPen® performance across the full spectrum of real-world conditions, including the challenging NAC environment that simulates scenarios patients may encounter during actual allergic reactions and, the timing of initiating its pivotal clinical study in the fourth quarter of 2026. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Forward-looking statements are based on the Company’s current expectations and are subject to uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s Registration Statement on Form F-1 filed with the U.S. Securities and Exchange Commission on March 2, 2026. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law. Company Contact Nasus Pharma Ltd. info@nasuspharma.com Investor Contact Mike Moyer LifeSci Advisors +1-617-308-4306 mmoyer@lifesciadvisors.com